Year 2022 / Volume 114 / Number 12
Letter
Protective measures against Omicron could be more effective than Evusheld® in liver transplant recipients

769-770

DOI: 10.17235/reed.2022.9058/2022

Aitor Odriozola Herrán, José Ignacio Fortea Ormaechea, Antonio Cuadrado, Ángela Puente Sánchez, Jeffrey V. Lazarus, Javier Crespo, Emilio Fábrega,

Abstract
Evusheld (the combination of cilgavimab and tixagevimab, two long-lasting monoclonal antibodies against SARS-CoV-2) has been approved by the FDA as a pre-exposure treatment for COVID-19 in immunocompromised patients older than 12 years. However, this monoclonal antibody has been developed from SARS-CoV-2 variants that were predominant at the beginning of the pandemic, when Ómicron was not prevalent. Compared with other solid organ transplant recipients, liver transplant recipients have shown an excellent immune response to standard vaccination with three doses of the SARS-CoV-2 vaccine. In addition, this population has shown very good adherence to protective measures for the transmission of COVID-19 infection. Several studies have shown that the use of Evusheld is less effective against Ómicron than against other variants of SARS-CoV-2. In addition, in the post-hoc analysis, it appears to be a drug that increases cardiovascular risk. For these reasons, we believe that in liver transplant recipients is essential to prioritize vaccination and protective measures, rather than the use of Evusheld as pre-exposure prophylaxis.
Share Button
New comment
Comments
No comments for this article
References
1. Boschi C, Colson P, Bancod A, Moal V, La Scola B. Omicron variant escapes therapeutic mAbs including recently released Evusheld ®, contrary to eight prior main VOC. Clin Infect Dis. 2022 Feb 16:ciac143. doi: 10.1093/cid/ciac143. Epub ahead of print. PMID: 35171987.
2. Odriozola A, Lamadrid-Perojo P, Cuadrado A, San Segundo D, Del Barrio M, Fortea JI, Puente A, Amigo L, Fernández-Santiago R, Castillo F, Achalandabaso M, Andrés Echeverri J, Rodríguez-Sanjuan JC, López-Hoyos M, Crespo J, Fábrega E. Immune Response After a Third Dose of the mRNA-1273 SARS-CoV-2 Vaccine in Liver Transplant Recipients. Transplantation. 2022 Mar 23. doi: 10.1097/TP.0000000000004147. Epub ahead of print. PMID: 35323163.
3. US Food and Drug Administration. Fact sheet for health care providers: Emergency Use Authorization for Evusheld (tixagevimab co-packaged with cilgavimab). Accessed December 21, 2021.
4. Odriozola A, San Segundo D, Cuadrado A, Hernáez T, Escrich V, Fortea JI, Martínez Á, Puente Á, Lapeña B, Del Barrio M, López-Hoyos M, Crespo J, Fábrega E. SARS-CoV-2 and Liver Transplant: How Has It Behaved in This Sixth Wave? Transplantation. 2022 Apr 8. doi: 10.1097/TP.0000000000004157. Epub ahead of print. PMID: 35394994.
5. Cuadrado A, Gaite LM, Odriozola A, Oloriz R, Herrera S, Fortea JI, Amigo L, Anderson EJ, Artal JA, Crespo J, Fábrega E. Impact of the COVID-19 lockdown on liver transplant recipients. A single center observational study. Rev Esp Enferm Dig. 2021 Sep 2. doi: 10.17235/reed.2021.8173/2021. Epub ahead of print. PMID: 34470450.
Related articles

Letter

Autoimmune hepatitis after SARS-C¬¬oV-2 vaccination

DOI: 10.17235/reed.2023.9579/2023

Digestive Diseases Image

Endosonographic and ERCP findings in COVID-19 critical illness cholangiopathy

DOI: 10.17235/reed.2022.9218/2022

Letter

Infection with SARS-CoV-2 as a potential achalasia trigger

DOI: 10.17235/reed.2022.8975/2022

Digestive Diseases Image

Acute respiratory failure secondary to megaesophagus: think beyond COVID-19

DOI: 10.17235/reed.2022.8847/2022

Letter

SARS-CoV-2 vaccine, a new autoimmune hepatitis trigger?

DOI: 10.17235/reed.2022.8820/2022

Letter

Surgical acute abdomen and COVID-19 vaccination

DOI: 10.17235/reed.2022.8721/2022

Letter

AMA-positive hepatitis induced by the SARS-CoV-2 vaccine.

DOI: 10.17235/reed.2022.8533/2021

Letter

A case of COVID-19 with concomitant infection with hepatitis A

DOI: 10.17235/reed.2021.8372/2021

Letter

COVID-19 and aorto-enteric fistula

DOI: 10.17235/reed.2021.8272/2021

Digestive Diseases Image

Portal thrombosis in a patient with SARS-CoV-2 infection

DOI: 10.17235/reed.2021.8099/2021

Letter

Autoimmune hepatitis triggered by COVID-19

DOI: 10.17235/reed.2021.8045/2021

Letter

Pneumoperitoneum and COVID-19. A causal association?

DOI: 10.17235/reed.2021.7877/2021

Letter

COVID-19 and the liver: the chicken or the egg dilemma

DOI: 10.17235/reed.2021.7861/2021

Letter

Acute pancreatitis related to SARS-CoV-2 infection. Disclaimer

DOI: 10.17235/reed.2021.7853/2021

Letter

Pancreatic injury and acute pancreatitis in COVID-19 patients

DOI: 10.17235/reed.2021.7807/2021

Editorial

Leading in turbulent times with the aim to serve

DOI: 10.17235/reed.2020.7684/2020

Letter

Pancreatic injury in COVID-19: pathogenesis and challenges

DOI: 10.17235/reed.2020.7541/2020

Letter

SARS-CoV-2 and acute pancreatitis: a new etiological agent?

DOI: 10.17235/reed.2020.7481/2020

Letter

Latin American authorship in scientific production on COVID-19

DOI: 10.17235/reed.2020.7432/2020

Letter

COVID-19. Immunothrombosis and the gastrointestinal tract

DOI: 10.17235/reed.2020.7292/2020

Letter

The effect of Adacolumn® on ulcerative colitis with COVID-19

DOI: 10.17235/reed.2020.7156/2020

Rapid reviews

COVID-19, coronavirus, SARS-CoV-2 and the small bowel

DOI: 10.17235/reed.2020.7137/2020

Citation tools
Odriozola Herrán A, Fortea Ormaechea J, Cuadrado A, Puente Sánchez Á, Lazarus J, Crespo J, et all. Protective measures against Omicron could be more effective than Evusheld® in liver transplant recipients. 9058/2022


Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Metrics
This article has received 1546 visits.
This article has been downloaded 83 times.

Statistics from Dimensions


Statistics from Plum Analytics

Publication history

Received: 05/07/2022

Accepted: 28/07/2022

Online First: 31/08/2022

Published: 12/12/2022

Article Online First time: 57 days

Article editing time: 160 days


Share
This article hasn't been rated yet.
Reader rating:
Valora este artículo:




Asociación Española de Ecografía Digestiva Sociedad Española de Endoscopia Digestiva Sociedad Española de Patología Digestiva
The Spanish Journal of Gastroenterology is the official organ of the Sociedad Española de Patología Digestiva, the Sociedad Española de Endoscopia Digestiva and the Asociación Española de Ecografía Digestiva
Cookie policy Privacy Policy Legal Notice © Copyright 2023 y Creative Commons. The Spanish Journal of Gastroenterology